Mobile website
Archive > Volume 23 Issue 4 > 2016,23(4):519-524. DOI:10.3872/j.issn.1007-385X.2016.04.011 Prev Next
Clinical Research
Clinical curative effect of DC-CIK immunocyte therapy for the patients with advanced breast cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the clinical efficacy and safety of dendritic cells (DCs) combined with cytokine-induced killer (CIK) cells in the treatment of advanced breast cancer, and to investigate the relevant prognostic factors. Methods: The clinical documents of 42 patients with advanced breast cancer that received DC/CIK treatment in 81st Hospital of PLA from August 2011 to December 2014 were retrospectively analyzed. Short-term curative effect was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) and the safety of DC-CIK therapy was observed. Overall survival of 42 patients was analyzed to evaluate the long-term curative effect. Univariate and multivariate analyses were used to analyze prognostic factors. The immunologic function was evaluated by paired T-test. Results: After the DC-CIK therapy, the overall response rate was 38.1% (16/42), the disease control rate was 61.9% (26/42), and the one-year, two-year and three-year survival rates were 59%, 48% and 48%, respectively. CA153 was significantly decreased after the treatment. In addition to a significant increase in the CD4+ level, the other peripheral blood lymphocyte subsets didn’t change significantly. Univariate analysis showed that the onset area (P=0.012) and the CA153 value before treatment (P=0.000) were the influence factors for the prognosis of cell immune therapy. Multivariate analysis showed that the CA153 value before treatment was an independent influence factor for the prognosis of cell immune therapy. Conclusion: The DC-CIK therapy is a safe and feasible therapeutic approach. It may improve the long-term survival rate of patients with advanced breast cancer.
Keywords:
Project Supported:
Projected supported by Program of Medical Science and Technology Innovation of Nanjing Military Area Command （No.14MS052）
Clc Number:
